Research programme: maytansine analogues - Kosan Biosciences
Latest Information Update: 04 Nov 2017
At a glance
- Originator Kosan Biosciences
- Class Macrolides
- Mechanism of Action DNA inhibitors; Mitosis inhibitors; Protein synthesis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 26 Apr 2007 Preclinical development is ongoing